Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease.

Abstract

Five parkinsonian patients with motor fluctuations and dyskinesia after long-term treatment with levodopa were treated with subcutaneous lisuride infusion (0.24-0.42 mg/day) together with oral levodopa for a mean period of 27 (range 13-36) months. All 5 patients showed marked initial improvement in mobility. Mild psychiatric side effects were observed in three patients; however, these side effects disappeared with reduction in the dosage of lisuride to 0.06 mg per day without a significant increase in motor fluctuations. A low dose of subcutaneous lisuride infusion with oral levodopa is an effective treatment for fluctuations of motor performance in parkinsonian patients without adverse psychiatric effects.

• Authors: R Hayashi, K Tako, H Makishita, J Koyama, N Yanagisawa
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 37 Issue 5 Pg. 444-8 (May 1998) ISSN: 0918-2918 [Print] Japan
• PMID: 9652898 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antiparkinson Agents
• Dopamine Agonists
• Levodopa
• Lisuride

Topics

• Administration, Oral
• Adult
• Antiparkinson Agents (administration & dosage)
• Dopamine Agonists (administration & dosage)
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Infusions, Parenteral
• Levodopa (administration & dosage)
• Lisuride (administration & dosage)
• Male
• Middle Aged
• Motor Activity (drug effects)
• Parkinson Disease (diagnosis, drug therapy, physiopathology)
• Severity of Illness Index
• Skin (drug effects)
• Treatment Outcome